In a world where doing a little bit of everything has become popular among drug companies, Mylan (MYL) has stuck to its guns. Unlike Teva (TEVA) and Sandoz (part of Novartis (NVS)), Mylan really is just about generic drugs and the opportunity to leverage one of the largest global franchises in that segment of the drug market. At the bottom line, Mylan is an interesting investment prospect, but really needs to deliver more to be a top choice.
Ending The Year In Line
Mylan did not offer a lot of surprises to close this fiscal year. Revenue rose about 7%, with generics up about 5% overall and the small (less than 10%) specialty business up almost 38%. The generics business was definitely a haves-and-have-not situation this quarter, as the North American business grew almost 13% on good volumes and strong pricing, while the European business saw revenue drop 12% on weak pricing.
Please click the link for the full piece:
Mylan Looks To Reap A Harvest Of Patent Expirations
No comments:
Post a Comment